ABSTRACT:
There are now major changes occurring in the treatment of chronic hepatitis C (HCV). The effectiveness and tolerability of traditional interferon-based therapy have been constrained, and a number of direct acting antiviral (DAA) medications are being developed. Phase II and III interferon-free clinical trials have now thoroughly assessed sofosbuvir (GS-7977), an HCV NS5B nucleotide polymerase inhibitor. The clinical potential of sofosbuvir in the treatment of HCV is the main topic of this review. Although sustained virological response (SVR) varies by virus genotype, sofosbuvir has a pan-genotypic effect on HCV, according to phase III clinical trials. Both dual therapy with ribavirin and triple therapy with either NS5A inhibitors or a protease inhibitor have been investigated for sofosbuvir. There have been reports of high SVR rates. Both cirrhotic and noncirrhotic patients have shown excellent safety profiles with no problems of viral resistance, and high rates of SVR have been documented with these interferon-free combinations, especially with genotypes 1 and 2. It is now possible to treat HCV once daily without the use of interferon.
Cite this article:
Tashvita P. Magare, Sunila A. Patil. Sofosbuvir, a NS5B Polymerase Inhibitor in the treatment of Hepatitis C: A Review of its Clinical Potential. Asian Journal of Pharmaceutical Research.2025; 15(4):411-7. doi: 10.52711/2231-5691.2025.00064
Cite(Electronic):
Tashvita P. Magare, Sunila A. Patil. Sofosbuvir, a NS5B Polymerase Inhibitor in the treatment of Hepatitis C: A Review of its Clinical Potential. Asian Journal of Pharmaceutical Research.2025; 15(4):411-7. doi: 10.52711/2231-5691.2025.00064 Available on: https://asianjpr.com/AbstractView.aspx?PID=2025-15-4-10
REFERENCES:
1. Cornpropst, M., et al. The effect of renal impairment and stage renal disease on the single-dose pharmacokinetics of PSI-7977. Hepatol. 56 (Suppl. 2): 2012: Abstract 1101.
2. Denning, J., et al. Lack of effect of the nucleoside analog polymerase inhibitor PSI-7977 on methadone PK and PD. Hepatology. 54(4): 2011: Abstract 372.
3. Fontaine, H., et al. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the French early access program (ANRS C020-CUPIC). Hepatol. 58 (S25-S44): 2013: A60.
4. Fontana, R., et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am f Transplant. 13: 2013: 1601-1605.
5. Gane, E., et al. Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir plus the NS5A Inhibitor GS-9669 Against HCV Genotype 1 Infection. Gastroenterology. 2013a: DOI: 10.1053/j.gastro.2013.11.007.
6. Gene, E., et al. All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study. F Hepatol. 58(S1-S24): 2013b: A14.
7. Gane, E., et al. Once daily sofosbuvir (GS-7977) plus ribavirinin patients with HCV genotypes 1, 2 and 3: the ELECTRON trial. Hepatology. 56(4 Suppl.): 2012: A229.
8. Gane, E., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl f Med. 368: 2013c: 34-44.
9. Gilead Sciences, Gilead reports interim data from phase 2 LONESTAR study: 2013: Available at: http://www.gilead.com/news/press-releases/2013/5/gilead-reports-interim-data-from-phase-2-lonestar-study.
10. Herbest, D., et al. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investing Drugs 22: 2013: 527-536.
11. Jacobson, I., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl f Med 368: 2013: 1867-1877.
12. Jacobson, I., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl f Med. 364: 2011: 2405-2416.
13. Kowdly, K., et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomized, multicenter phase 2 trial. Lancet. 381: 2013: 2100-2107.
14. Kuntzen, T., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 48: 2008: 1769-1778.
15. Lam, A., et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 56: 2012: 3359-3368.
16. Lawitz, E., et al. COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders In: Proceedings of the CROI: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA: 2013b.
17. Lawitz, E., et al. Sofosbuvir in combimation with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial. Lancet Infect Dis 13: 2013c: 401-408.
18. Lawitz, E., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl f Med. 368: 2013d: 1878-1887.
19. Lawitz, E., et al. The effect of hepatic impairment on the pharmacokinetics and antiviral antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days. F Hepatol. 56 (Suppl. 2): 2012: Abstract 1130.
20. Mathias, A., et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers. Hepatology. 56 (4 Suppl.): 2012: Abstract 1869.
21. Medivir, Medivir announces interim results from cohort 2 of the COSMOS study evaluating Simeprevir and Sofosbuvir in HCV patients with METAVIr scores F3-F4, Press Release: 2013: Available at: http://www.medivir.se/v5/en/uptodate/pressrelease.cfm?releaseid=FEBC5055C8C2C046andyear=2013.
22. Murakami, E., et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. F Biol Chem 285: 2010: 34337-34347.
23. Poordad, F., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl f Med 364: 2011: 1195-1206.
24. Rodriguez-Torres, M., et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-days, dose-ranging trial. F Hepatol 58: 2013: 663-668.
25. Sofia, M., et al. Discovery of a beta-d-2’-deoxy-2’-alpha-fluoro-2’-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. F Med Chem 53: 2010: 7202-7218.
26. Sulkowski, M., et al. Sustained virological response with daclatasvir, plus sofosbuvir +- ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). F Hepatol. 58 (S567-S577): 2013: Abstract 1417.
27. Younossi, Z., St et al. Minimal impact of sofosbuvir + ribavirin on health related quality of life (HRQL) compared to pegylated interferon + ribavirin for chronic hepatitis C: results from FISSION + POSITRON trials. F Hepato; 58(S567-S577): 2013: Abstract 1431.